PE-22-28

PE-22-28 is a short neuropeptide with demonstrated effects in cognitive enhancement, neuroprotection, and mood stabilization. It acts by regulating gene expression and protein synthesis in neurons and has shown positive outcomes in memory, focus, and anxiety models. It is typically administered via subcutaneous injection and has a favorable safety profile in animals.

• Enhances gene expression related to neuroplasticity and memory
• Modulates protein synthesis in hippocampal neurons
• Stimulates neurotrophin (e.g. BDNF) production in cortical brain regions
• Protects neurons from oxidative damage and apoptosis

• unit: mcg

  low dose: 200

  frequency: Daily

  high dose: 600

  standard dose: 400

  administration route: Subcutaneous (SQ)

• Recommended cycle: 4–6 weeks of daily use. Can be repeated every 2–3 months with a 2–4 week rest period.

common: ["Mild GI discomfort, nausea, headache — all very uncommon (preclinical extrapolation)"]

warnings: ["Theoretical risk of sedation or blunted motivation with overdosing (animal data)"]

sequence: Lys-Gly-Asn

half life: Approximately 6 hours

degradation: Metabolized primarily in liver and neural tissues

molecular weight: 200.25

molecular formula: C10H16N2O3

tissue specificity: Targets hippocampus, cortex, and brain regions related to cognition and neuroinflammation

• Shortened Spadin Analogs Display Better TREK-1 Inhibition, Stability and Antidepressant Activity.mechanismPMID 28955242 ↗